Printer Friendly

BIO-IMAGING TECHNOLOGIES APPOINTS MARC FISHER, M.D., TO ITS SCIENTIFIC ADVISORY BOARD

 Pioneer in New Brain Scanning Techniques for
 Stroke to Provide Insights on New Drug Development
 WEST TRENTON, N.J., Sept. 29 /PRNewswire/ -- Bio-Imaging Technologies, Inc. (NASDAQ Small Cap: BITI) announced today that Marc Fisher, M.D., a distinguished neurologist and a pioneer in the development of new brain imaging techniques for the study of stroke, has joined the company's Scientific Advisory Board.
 Fisher, who serves currently as professor of neurology and professor of radiology at the University of Massachusetts Medical School in Worcester, Mass., is a leading investigator studying advanced brain imaging methods for the diagnosis and treatment of stroke. Using an experimental magnetic resonance imaging (MRI) technique called diffusion-weighted imaging, Fisher and his group were among the first to follow the timecourse of strokes in progress. The new technique enables brain researchers to visualize the extent of brain tissue damage associated with strokes and other forms of brain trauma. The technique relies heavily upon computerized image processing and image analysis.
 Using the diffusion-weighted MRI technique, Fisher and his collaborators hope to facilitate the development of new drugs to protect brain cells from the damaging effects of stroke, a leading cause of death in the United States. These so-called "neuroprotectant" drugs hold promise to protect brain cells from the harmful cascade of cellular events in the crucial hours following stroke onset. Leading drug candidates are now being developed by over 20 major pharmaceutical and biotechnology companies.
 "We are honored by Dr. Fisher's participation on our Scientific Advisory Board," commented James J. Conklin, M.D., C.E.O. and chairman of Bio-Imaging Technologies. "This event signifies an important acknowledgment by one of academic neurology's leading researchers that advanced medical imaging and image analysis techniques as put to practice by our company can play an integral role in the development of new diagnostics and therapeutics for neurologic disease and other conditions."
 Bio-Imaging Technologies applies proprietary computer and imaging technologies to process, analyze and database large amounts of medical imaging data (MRIs, CAT scans, nuclear medicine scans) generated during the pre-clinical development and clinical testing process for drugs and medical devices. The company is targeting drug and biotech companies including those developing new central nervous system compounds, and counts among its clients, Janssen Pharmaceutica Research Foundation and Marion Merrell Dow.
 Speaking of his new advisory role with the company, Fisher said, "We have entered a period where advanced imaging tools will help to elucidate the mysteries of brain disease, giving clinicians and patients greater opportunity for early diagnosis and effective treatment. I am deeply interested in the ability of imaging technologies to aid drug development, and believe that companies like Bio-Imaging Technologies can have a major impact on the development of new therapies."
 Fisher, a Massachusetts native, earned a B.S. with distinction from Cornell University and his M.D. from The State University of New York at Syracuse. He has held numerous academic and clinical appointments at the University of Massachusetts Medical School and the Medical Center of Central Massachusetts. Fisher is a Fellow of the American Academy of Neurology, and serves on the Stroke Council of the American Heart Association. An author of more than 80 publications and an international lecturer on cerebrovascular disease, Fisher also serves on the editorial board of numerous specialty journals.
 Fisher joins five other Scientific Advisory Board Members at Bio- Imaging Technologies, including fellow University of Massachusetts Medical School professor and nuclear medicine expert, Aaron B. Brill, M.D., Ph.D., James L. Lear, M.D. a radiologist and nuclear medicine expert, Albert LoBuglio, M.D., a cancer expert, Francis D. Moore, M.D., a distinguished surgeon emeritus, and Henry N. Wagner, M.D., a pioneering nuclear imaging specialist.
 Bio-Imaging Technologies of West Trenton applies advanced medical imaging technologies and computer-assisted image analysis techniques to visualize and measure drug and medical device effects during the clinical development and pre-clinical testing process. The company's technology can help to accelerate the development and regulatory review of new therapeutic and diagnostic agents and devices by providing more precise analyses from a smaller number of study subjects. The company provides its medical image processing and digital image management expertise to the pharmaceutical, biotechnology and medical device industries.
 /delval/
 -0- 9/29/93
 /CONTACT: William L. Robbins, director, Business Development, or Andrea M. Cichetti, assistant, Business Development, of Bio-Imaging, 609-883-2000/
 (BITI)


CO: Bio-Imaging Technologies, Inc. ST: New Jersey IN: CPR SU: PER

CC -- PH001 -- 6626 09/29/93 07:33 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 29, 1993
Words:740
Previous Article:NEWSPAPER GUILD OF GREATER PHILADELPHIA ANNOUNCES STRIKE AT NORRISTOWN TIMES AND HERALD
Next Article:NEW OFFICE LASER TREATMENT FOR SNORING PRESENTED AT ANNUAL OTOLARYNGOLOGY CONFERENCE
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters